维普中文期刊产品整合服务
17篇 您的检索式:作者名="WERMKE M"
    题名 作者 年代 出处 被引量
1Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia显示文摘Steudel C Wermke M Schaich M 2003Genes Chromosomes Cancer2003,37,:1
2Comparative a- nalysis of MLL partial tandem duplication and FLT3 in- ternal tandem duplication mutationsin 956 adult patients with acute myeloid leukemia显示文摘Steudel C Wermke M Schaich M 2003Genes Chromosomes Cancer2003,37,3:1
3Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneie HSCT:results of the RELAZA trial显示文摘Platzbecker U Wermke M Radke J 2012Leukemia2012,26,3:1
4Fermenta- tion pattern and changes in cell wall constituents of straw-forage silages, straws and partners during storage 显示文摘SINGH K HONIG H WERMKE M 1996Animal Feed Science and Technology1996,61,1234:1
5Successful eradication of acquired factor-Ⅷ -inhibitor using single low-dose rituximab显示文摘WERMKE M VON BM GEHRISCH S 2010Haematologica2010,95,3:1
6Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia显示文摘Steudel C Wermke M Schaich M 2003Genes Chromosomes Cancer2003,37,3:1
7Azacitidine fortreatment of imminent relapse in MDS or AML patients afterallogeneic HSCT:results of the RELAZA trial显示文摘Platzbecker U Wermke M Radke J 2012Leukemia2012,26,3:1
8Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome显示文摘von Dalowski F Kramer M Wermke M 2016Stem Cells2016,34,2:1
9Genetic variations of interleukin-23R (l143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation显示文摘Wermke M Maiwald S Schmelz R 2010Biol Blood Marrow Transplant2010,16,12:1
10Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial 显示文摘Platzbecker U Wermke M Radke J 2012Leukemia2012,26,3:1
11Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial 显示文摘PLATZBECKER U WERMKE M RADKE J 2012Leukemia2012,26,3:1
12Comparative analysis ofMLL partial tandem duplication and FLT3 internal tandemduplication mutationsin 956 adult patients with acute myeloidleukemia 显示文摘Steudel C Wermke M Schaich M 2003Genes Chromosomes Cancer2003,37,3:1
13Comparative analysis of MLL partial tandem duplication and Flt-3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia 显示文摘Steudel C Wermke M Schaich M 2003Genes Chromosomes Cancer2003,37,3:1
14Azacitidine for treat- ment of imminent relapse in MDS or AML patients after allogeneic HSCT : results of the RELAZA trial显示文摘Platzbecker U Wermke M Radke J 2012Leukemia2012,26,3:1
15Successful treatment of molec- ular relapse in NPMl-positive AML using 5-azacytidine显示文摘Wermke M Thiede C Kiani A 2010Leukemia2010,24,1:1
16MRI-based liver iron content predicts for nonrelapse mortality in MDS and AMLpatients undergoing allogeneic stem cell transplantation显示文摘Wermke M Schmidt A Middeke JM 2012Clin Cancer Res2012,18,64:1
17Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT:results of the RELAZA trial显示文摘Platzbecker U Wermke M Radke J 2012Leukemia2012,26,3:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费